DDInter188 DDInter1376
Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Benzthiazide {u} (Compound) resembles {v} (Compound) Metolazone
Benzthiazide {u} (Compound) resembles {v} (Compound) Trichlormethiazide
Benzthiazide {u} (Compound) binds {v} (Gene) CA1
Benzthiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glycopyrronium
Benzthiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trospium
Benzthiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Benzthiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Benzthiazide {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Benzthiazide (Compound) resembles Metolazone (Compound)
Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Benzthiazide (Compound) binds CA1 (Gene)
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Trospium
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Benzthiazide may lead to a major life threatening interaction when taken with Dolasetron